Systemic Therapies for Advanced Melanoma

Bomar, Leonora; Senithilnathan, Aditi; Ahn, Christine S.

doi:10.1016/j.det.2019.05.001

Cited by 47 publications

(48 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Melanoma patients with distant metastases show a 5-year survival rate of 23%, making metastasis the leading cause of melanoma-associated deaths [17].…”

Section: Metastatic Melanomamentioning

confidence: 99%

“…The new immunotherapy is the treatment that has been most extensively studied in metastatic melanoma [ 53 ]. Immunotherapy can be divided into four main groups [ 17 ]. The first include biological medications such as cytokines, interferons, and granulocyte-monocyte colony-stimulating factors [ 54 ].…”

Section: Immunotherapy For Metastatic Melanomamentioning

confidence: 99%

“…Another novel issue is the evaluation of response and the identification of the endpoints. Indeed, Ipilimumab was the first drug to show improvement in OS for over 30 years, despite its impact on the ORR and the fact that progression-free survival (PFS) did not match the survival benefits achieved [ 4 , 17 , 39 , 98 ]. This effect of OS was also shown with Nivolumab in kidney cancer [ 103 ].…”

Section: Immunotherapy For Metastatic Melanomamentioning

confidence: 99%

See 2 more Smart Citations

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Ralli

Botticelli

Visconti

et al. 2020

Journal of Immunology Research

149

138

View full text Add to dashboard Cite

Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy. Immunotherapy is associated to a panel of dysimmune toxicities called immune-related adverse events that can affect one or more organs and may limit its use. Future directions in the treatment of metastatic melanoma include immunotherapy with anti-PD1 antibodies or targeted therapy with BRAF and MEK inhibitors.

show abstract

“…Melanoma patients with distant metastases show a 5-year survival rate of 23%, making metastasis the leading cause of melanoma-associated deaths [17].…”

Section: Metastatic Melanomamentioning

confidence: 99%

Section: Immunotherapy For Metastatic Melanomamentioning

confidence: 99%

Section: Immunotherapy For Metastatic Melanomamentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Ralli

Botticelli

Visconti

et al. 2020

Journal of Immunology Research

149

138

View full text Add to dashboard Cite

show abstract

“…Vemurafenib was the first to be approved by the Food and Drug Administration (FDA) in 2011 for metastatic melanoma with the BRAF V600E mutation. 76 In clinical trials, progression free survival (PFS) and median OS were significantly higher for vemurafenib compared to chemotherapy (PFS 6.9 months vs 1.6 months, median OS 13.6 months vs 9.7 months for vemurafenib vs chemotherapy, respectively). 77 Then, in 2013, dabrafenib was FDA approved for the same indication and demonstrated PFS of 5.1 months compared to 2.7 months with chemotherapy.…”

Section: Management Of Sentinel Lymph Node-positive Melanomamentioning

confidence: 99%

“…80 Thus, BRAF inhibitors are often combined with MEK inhibitors like trametinib, binimetinib and cobimetinib. 76 There are three FDAapproved combinations of BRAF and MEK inhibitor combination therapy: dabrafenib plus trametinib, vemurafenib plus cobimetinib, and encorafenib plus binimetinib. All approved combinations have superior survival rates compared to BRAF or MEK inhibitor monotherapy.…”

Section: Management Of Sentinel Lymph Node-positive Melanomamentioning

confidence: 99%

Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions

Fayne¹,

Macedo²,

Rodgers³

et al. 2019

Oncol Rev

View full text Add to dashboard Cite

Sentinel lymph node (SLN) biopsy has become the standard of care for lymph node staging in melanoma and the most important predictor of survival in clinically node-negative disease. Previous guidelines recommend completion lymph node dissection (CLND) in cases of positive SLN; however, the lymph nodes recovered during CLND are only positive in a minority of these cases. Recent evidence suggests that conservative management (i.e. observation) has similar outcomes compared to CLND. We sought to review the most current literature regarding the management of SLN in metastatic melanoma and to discuss potential future directions.

show abstract